Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?

Annals of Oncology

Volumn 13, Issue 2, 2002, Pages 318-322

  Barista, I ^a   Cabanillas, F ^a   Romaguera, J E ^a   Khouri, I F ^a   Yang, Y ^a   Smith, T L ^a   Strom, S S ^a   Medeiros, L J ^a   Hagemeister, F B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Additional neoplasm; Mantle cell lymphoma; Second malignancy

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER INVASION; CARCINOMA IN SITU; CLINICAL OBSERVATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MENINGIOMA; PRIORITY JOURNAL; SECOND CANCER; URINARY TRACT CANCER; UTERINE CERVIX CANCER; UTERINE CERVIX EPITHELIUM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY;

EID: 0036299645     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf042     Document Type: Article

References (26)

1. The incidence of multiple primary cancers. I. Development of further cancers in patients with lymphomas, leukemias, and myeloma
2. Second cancers following non-Hodgkin's lymphoma
3. Second cancers among long-term survivors of non-Hodgkin's lymphoma
4. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data
5. Evidence for need of upper and lower endoscopies with biopsy in staging of asymptomatic patients with aggressive mantle cell lymphoma (MCL)
6. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle cell lymphoma
7. Preliminary report of Rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma (MCL)
8. The statistical analysis of failure time data
9. Non-parametric estimation from incomplete observations
10. Mantle cell lymphoma: A retrospective study of 121 cases
11. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: A 3-year follow-up study
12. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma
13. Malignant neoplasms following bone marrow transplantation
14. Therapy-related leukemia and myelodysplastic syndrome: Clinical, cytogenetic, and prognostic features
15. The molecular pathogenesis of treatment-induced (secondary) leukemias: Foundations for treatment and prevention
16. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma
17. Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma
18. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma
19. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies
20. Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT. EBMT Lymphoma and Late Effects Working Parties
21. Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: A report of six cases in a cohort of 171 patients from a single institution
22. An association between renal cell carcinoma and lymphoid malignancies. A case series of eight patients
23. Coincident renal cell carcinoma and non-Hodgkin's lymphoma: The M.D. Anderson experience and review of the literature
24. p53 mutations in cyclophosphamide-associated bladder cancer
25. Coexistence of renal cell carcinoma and malignant lymphoma. A causal relationship or coincidental occurrence?